USA: A new study published in the Journal of Diabetes and Its Complications suggests that tirzepatide, a novel dual ...

Tirzepatide has emerged as the most effective treatment for lowering blood sugar and promoting weight loss in people with type 2 diabetes, according to a major new study published in Scientific ...

Of 609 men surveyed, 19% continued to have erectile dysfunction after being hospitalized with COVID-19. Nearly half still had ED after two years.

Data from a limited number of trials hint that GLP-1 use might improve erectile dysfunction and testosterone levels for men, but more research is needed to provide a clearer picture, researchers ...

In a study in the Journal of Clinical Medicine, a certain group of men actually improved their erectile function and sperm count over four months—but the men were specifically those with obesity ...

A new head-to-head study of tirzepatide versus semaglutide for weight loss in people living with obesity, but not diabetes, shows that over 72 weeks tirzepatide results in an average weight loss ...

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for weight loss in a head-to-head trial with semaglutide (Ozempic, Wegovy).

The health study found medications commonly prescribed for erectile dysfunction are associated with significant reductions in deaths, cardiovascular disease, and dementia ...

In the US alone approximately 30 million men are living with erectile dysfunction while an estimated 2 out of every 100 American males is not producing testosterone within a typical healthy range ...

The authors note that other classes of drugs have been found to cause NAION, including erectile dysfunction and anti-arrhythmia drugs. In some cases, research has led to changes in labeling.

Tirzepatide, the active ingredient in these diabetes and weight loss drugs, slashed the likelihood of hospitalization and death in a new study.